BMRA | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 13%

Liquidity 53%

Performance 40%

Company vs Stock growth

1.807 M 1.636 M

-171.000 K -9.46%

0.321 0.328

0.007 2.02%

+ Add row to compare

Performance

5 Days

-3.16%

1 Month

-20.77%

3 Months

38.44%

6 Months

46.88%

1 Year

-41.31%

2 Year

-73.09%

Key data

Stock price

$0.48

P/E Ratio

0.00

DAY RANGE

$0.47 - $0.53

EPS

-$0.32

52 WEEK RANGE

$0.24 - $1.27

52 WEEK CHANGE

-$40.20

MARKET CAP

6.552 M

YIELD

N/A

SHARES OUTSTANDING

16.822 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.12

PUBLIC FLOAT

AVERAGE 10 VOLUME

$145,296

AVERAGE 30 VOLUME

$175,895

Company detail

CEO: Zackary S. Irani
Region: US
Website: biomerica.com
Employees: 60
IPO year: 2007

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests.

BMRA - BIOMERICA INC